DermatologistsBlog.com Interview with Ibrahim Khalifeh, M.D., A.B.D. Assistant ProfessorGeneral, Cytopathology and DermatopathologyAmerican University of Beirut Medical CenterBeirut, Lebanon 1107 2020 Dr. Khalifeh: The points I would like to highlight in our retrospective study: - This study is considered by far the largest series of BRAF analysis in dysplastic nevi. Our study is composed of 125 cases. [...]
All posts in category BRAF
BRAF mutational epidemiology in dysplastic nevi: Does different solar UV radiation exposure matter?
Posted by admin on March 27, 2013
http://dermatologistsblog.com/skin-cancer/braf-mutational-epidemiology-in-dysplastic-nevi-does-different-solar-uv-radiation-exposure-matter/
Prevalence of BRAF and NRAS mutations in fast growing melanomas
DermatologistsBlog.com Author Interview: Dr. Eduardo Nagore Department of Dermatology Instituto Valenciano de Oncología 46009 Valencia Spain DermatologistsBlog.com: What are the main findings of the study? Dr. Nagore: Around 20% of melanomas grow very fast, i.e. increasing in depth more than 0,5 mm per month. This subset of melanomas has been demonstrated to have worse prognosis [...]
Posted by admin on March 5, 2013
http://dermatologistsblog.com/skin-cancer/prevalence-of-braf-and-nras-mutations-in-fast-growing-melanomas/
Vemurafenib induces senescence features in melanoma cells
Vemurafenib induces senescence features in melanoma cells. DermatologistsBlog.com Author Interview: Dr. rer. nat. Svenja Meierjohann Universität Würzburg Theodor-Boveri-Institut für Biowissenschaften Physiologische Chemie I Am Hubland D – 97074 Würzburg and Dr. med. Sebastian Haferkamp Universitätsklinikum Würzburg Klinik und Poliklinik für Dermatologie, Venerologie und AllergologieJosef-Schneider-Straße 297080 Würzburg DermatologistsBlog.com: What are the main findings of the study? [...]
Posted by admin on January 29, 2013
http://dermatologistsblog.com/skin-cancer/vemurafenib-induces-senescence-features-in-melanoma-cells/
Desmoplastic Malignant Melanoma: A Study of Ten Cases and Status of BRAF Mutation.
Desmoplastic Malignant Melanoma: A Study of Ten Cases and Status of BRAF Mutation DermatologistsBlog.com Author Interview: Pr Michel D’INCAN, MD, PhD Dermatology CHU- Hôpital Estaing 1, place Lucie et Raymond Aubrac F-63003 Clermont-Ferrand cedex 01 France DermatologistsBlog.com: What are the main findings of the study? Desmoplastic melanoma is a rare variant of spindle cell melanoma [...]
Posted by admin on November 29, 2012
http://dermatologistsblog.com/skin-cancer/melanoma/desmoplastic-malignant-melanoma-a-study-of-ten-cases-and-status-of-braf-mutation/
Cutaneous Manifestations of Dabrafenib, a mutant BRAF inhibitor for Metastatic Melanoma
Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma DermatologistsBlog.com Author Interview: Dr R.Anforth, BMed, BAppSc Department of Dermatology, Westmead Hospital, Sydney Australia University of Sydney, Sydney Australia DermatologistsBlog.com: What are the main findings of the study? The new generation RAF inhibitor dabrafenib has a number of cutaneous [...]
Posted by admin on October 18, 2012
http://dermatologistsblog.com/skin-cancer/cutaneous-manifestations-of-dabrafenib-a-mutant-braf-inhibitor-for-metastatic-melanoma/
Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations.
Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. Author Interview: Paolo Antonio Ascierto, MD Meeting Presentation: 2012 ASCO Annual Meeting Session Type and Session Title: Clinical Science Symposium, Mutated Melanoma: The Role for MEK Inhibitors J Clin Oncol 30, 2012 (suppl; [...]
Posted by admin on June 23, 2012
http://dermatologistsblog.com/skin-cancer/efficacy-and-safety-of-oral-mek162-in-patients-with-locally-advanced-and-unresectable-or-metastatic-cutaneous-melanoma-harboring-brafv600-or-nras-mutations/
Metformin – BRAF & Melanoma
Metformin Accelerates the Growth of BRAFV600E-Driven Melanoma by Upregulating VEGF-A Author Interview: Richard Marais PhD, FMedSci Director, Paterson Institute for Cancer Research | Wilmslow Road | The University of Manchester | Manchester M20 4BX | United Kingdom What are the main findings of the study? • When grown in culture metformin has little effect on [...]
Posted by admin on April 6, 2012
http://dermatologistsblog.com/skin-cancer/metformin-braf-melanoma/
Categories
Dermatology Author Interviews
Twitter
National Eczema Association
National Eczema Association
Pages
-
Dermatology Research Studies from NIH
Dermatology Meetings & Skin Care Events
May 2013 M T W T F S S 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 Categories
AAD 2012 Dermatology Interviews AAD American Academy Dermatology Acne Actinic Keratosis Aging Skin Allergies Alopecia - Atopic Dermatitis - Eczema Author Interviews Basal Cell Carcinoma Bedbugs Biologics Botulinum Toxin - Botox BRAF Connective Tissue Disease Contact Dermatitis Cosmeceuticals Cosmetics Cosmetic Surgery Eczema FDA Announcements Genetic Research Head Lice Herpes Zoster/Shingles HPV Infections Itch Lyme Medications Melanoma MRSA National Psoriasis Foundation Pediatric Dermatology Psoriasis Psoriatic Arthritis Skin Cancer Squamous Cell Cancer Stem Cells Sunburns Sunscreens Tanning Booths UV Light Vitamin D Vitiligo Warts_Papilloma Virus-
